Improved Survival with Ipilimumab in Patients with Metastatic Melanoma¶
Why this mattered¶
Before this trial, metastatic melanoma was a disease in which survival gains had repeatedly failed to materialize, and cancer immunotherapy was still widely viewed as promising but clinically unreliable. Hodi et al. showed in a randomized phase 3 setting that blocking CTLA-4 with ipilimumab could extend overall survival in previously treated metastatic melanoma, even though conventional response rates were modest and toxicity was substantial. The important shift was not simply that one drug improved median survival from about 6.4 to 10 months versus gp100 alone, but that manipulating an immune checkpoint could produce a survival benefit in advanced solid cancer.
The paper helped change the central therapeutic question in oncology from “Can the immune system recognize cancer?” to “Which inhibitory pathways must be released, in which patients, and at what cost?” It established immune checkpoint blockade as a clinically valid strategy, while also making clear that immune activation brought a distinct toxicity profile: colitis, endocrinopathies, hepatitis, dermatitis, and other immune-related adverse events that required new management norms. This made possible a new clinical language around delayed responses, durable benefit, reinduction, and immune-mediated adverse events, none of which fit comfortably into the older cytotoxic chemotherapy framework.
Its influence is best understood as the opening clinical proof for the checkpoint era. Ipilimumab was later followed by PD-1 and PD-L1 inhibitors, which produced higher response rates and broader applicability across melanoma and many other cancers, and by combination regimens such as CTLA-4 plus PD-1 blockade. Those later breakthroughs did not make this study obsolete; they depended on the conceptual and regulatory path it helped create: that releasing immune inhibition could improve survival in metastatic cancer and that randomized survival evidence, not tumor shrinkage alone, could validate immunotherapy as a major pillar of oncology.
Abstract¶
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)
Related¶
- enables → Pembrolizumab versus Ipilimumab in Advanced Melanoma — Ipilimumab's survival benefit established CTLA-4 checkpoint blockade as a melanoma benchmark against which pembrolizumab's PD-1 blockade was compared.
- enables → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer — Ipilimumab's survival benefit validated immune-checkpoint blockade in cancer, enabling pembrolizumab trials targeting PD-1 in non-small-cell lung cancer.
- enables → Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer — Ipilimumab proved checkpoint blockade could improve melanoma survival, supporting the broader immunotherapy framework used to link tumor mutational burden with PD-1 response.
- enables → Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer — The ipilimumab trial proved that immune checkpoint blockade can improve survival in metastatic cancer, supporting later PD-1 blockade testing with pembrolizumab in lung cancer.
- enables → Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma — Ipilimumab's survival benefit established CTLA-4 checkpoint blockade as a melanoma therapy tested in combination with nivolumab.
- enables → Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer — The ipilimumab melanoma trial enables the nivolumab lung-cancer trial by clinically validating immune-checkpoint blockade as an anticancer strategy.
- cite ← Pembrolizumab versus Ipilimumab in Advanced Melanoma — The pembrolizumab melanoma trial compares against ipilimumab, whose survival benefit established CTLA-4 blockade as an active melanoma therapy.
- cite ← Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation — The vemurafenib melanoma trial contrasts targeted BRAF inhibition with the survival benchmark established by ipilimumab immunotherapy in metastatic melanoma.
- cite ← Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer — The pembrolizumab lung cancer study cites ipilimumab as prior evidence that immune checkpoint inhibition can improve survival in cancer.
- cite ← Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer — The NSCLC PD-1 study cites ipilimumab as clinical evidence that immune checkpoint blockade can improve survival in cancer.
- cite ← Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer — The anti-PD-1 study builds on ipilimumab's CTLA-4 survival benefit to frame PD-1 blockade as another immune-checkpoint strategy for cancer therapy.
- cite ← Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer — The pembrolizumab NSCLC trial cites ipilimumab melanoma survival gains as clinical evidence that immune checkpoint blockade can improve cancer outcomes.
- cite ← Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma — The nivolumab-ipilimumab trial builds on ipilimumab's demonstrated survival benefit as an immune-checkpoint therapy in metastatic melanoma.
- cite ← Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer — The anti-PD-L1 trial cites ipilimumab as clinical evidence that immune checkpoint blockade can improve survival in metastatic melanoma.
- cite ← Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer — The nivolumab trial cites ipilimumab survival data as precedent that immune checkpoint inhibition can improve overall survival in advanced cancer.